The Transactions Haven’t Changed. The Network Has. Flying home from the HDA Traceability Seminar last week, I saw some news from Philadelphia that put much of what we had spent the previous few days discussing […]

What comes next for DSCSA OPERATIONS AND INTEROPERABILITY Thirteen years after DSCSA became law, the industry’s focus is shifting from implementation to sustained operation. At the 2026 HDA Traceability Seminar, discussions increasingly centered on what […]

Wholesale distributors play a pivotal role in safeguarding the integrity of the U.S. pharmaceutical supply chain under the Drug Supply Chain Security Act (DSCSA). The Rx‑360 DSCSA Readiness Checklist for Distributors distills core requirements into […]

The BIOSECURE Act did not arrive with ceremony. It arrived embedded in the National Defense Authorization Act, debated largely in abstractions, and passed with little public attention. But for pharmaceutical and biotechnology companies operating global […]

As China continues to evolve its pharmaceutical regulatory landscape, organizations operating within or in partnership with the Chinese market must proactively adapt to remain compliant and competitive. The National Medical Products Administration (NMPA) has outlined […]

In a significant move to reshape its pharmaceutical landscape, China has unveiled a comprehensive guideline aimed at deepening the reform of drug and medical device regulation. Issued by the General Office of the State Council […]

Get the tools you need for breaking down the barriers that hold the world back from optimal movement of critical goods and materials. Download the index document to access the video modules listed below that […]

“Prevention of Reuse of Genuine Packaging Components for Counterfeit Products” addresses the growing threat of counterfeit pharmaceutical products entering the legitimate supply chain through the reuse of genuine packaging components. Counterfeiters often retrieve discarded packaging—such […]